Soft tissue sarcomas are a rare and multifaceted group of solid tumours. Neoadjuvant
chemotherapy is increasingly used to limit loss of function after wide surgical excision with …

PURPOSE To determine whether the administration of histology-tailored neoadjuvant
chemotherapy (HT) was superior to the administration of standard anthracycline plus …

Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper
perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted …

Primary therapy for soft tissue sarcoma is predicated on surgical resection with an adequate
margin of normal tissue. For high-risk patients, local control is improved with postoperative …

Background The prognostic role of tumor necrosis following neoadjuvant therapy is
established in bone sarcomas but remains unclear in soft tissue sarcomas (STS). Methods …

Background The purpose of this study was to retrospectively analyze the relationship
between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade …

BACKGROUND: The use of neoadjuvant and adjuvant chemotherapy in soft tissue
sarcomas is controversial. This is a report of long‐term (≥ 5 years) follow‐up in patients with …

Background Previous trials from our group suggested an overall survival benefit with five
cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue …

Background The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not
completely understood. This study investigated the benefit of neoadjuvant chemotherapy …

At present, there is not a commonly used and generally accepted standardized approach for
the pathologic evaluation of pretreated soft tissue sarcomas. Also, it is still unclear whether …